A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

• ClinicalTrials.gov Identifier: NCT03728556
• Recruitment Status: Completed
• First Posted: November 2, 2018
• Last Update Posted: June 15, 2023
• Sponsor: CStone Pharmaceuticals
• Information provided by (Responsible Party): CStone Pharmaceuticals

Study Description

Brief Summary:

This is a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of CS1001 in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.

Condition or disease	Intervention/treatment	Phase
Non-Small Cell Lung Cancer Stage III	Biological: CS1001 monoclonal antibody; Biological: CS1001 placebo	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 381 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Has Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy
• Actual Study Start Date: October 26, 2018
• Actual Primary Completion Date: April 3, 2023
• Actual Study Completion Date: April 3, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: CS1001monoclonal antibody	Biological: CS1001 monoclonal antibody; Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months
Placebo Comparator: CS1001 Placebo	Biological: CS1001 placebo; Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months

Outcome Measures

Primary Outcome Measures :

1. Progress Free Survival (PFS) [ Time Frame: from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months. ]
   The primary endpoint is the PFS of CS1001 versus placebo (evaluated by blinded independent central review(BICR) according to response evaluation criteria in solid tumors RECIST v1.1).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Willing to participate in this trial; fully understand and informed of this trial, and able to provide written informed consent form (ICF).
2. ≥ 18 years of age on the day of signing ICF.
3. Have histologically confirmed locally advanced/unresectable stage III non-small cell lung cancer.
4. The first dose of CS1001 will be administered within 1 - 42 days (including 42 days) after concurrent/sequential chemoradiotherapy is completed.
5. Platinum-containing chemotherapy.
6. Absence of progression after concurrent/sequential chemoradiotherapy.
7. Eastern Cooperative Oncology Group(ECOG) Perfomance Status (PS) of 0 or 1.
8. Life expectancy ≥ 12 weeks.
9. Subject with prior anti-cancer treatment can only be enrolled when all toxicities except for hearing loss, alopecia and fatigue, of prior anti-cancer treatment has recovered to baseline or ≤ Grade 1 (according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v4.03).
10. Subjects must have adequate organ function as assessed in the following laboratory tests.
11. Women of childbearing potential or fertile men must agree to use an effective method of birth control from providing signed ICF and for 180 days after last dose of investigational product. Women of childbearing potential include premenopausal women and women whose menopause started within prior 2 years. Women of childbearing potential must have a negative pregnancy test ≤7 days prior to the first dose of experimental drug.

Exclusion Criteria:

1. Histologically identified to have mixed small cell lung cancer component.
2. Disease progression after concurrent/sequential chemoradiotherapy.
3. Major surgical procedure (as determined by investigators) within 28 days prior to the first dose of investigational product.
4. Has received a live vaccine within 28 days prior to the first dose of investigational product.
5. Current participation in another clinical study or use of any investigational drug within 28 days prior to the first dose of investigational product in this trial. (Participation in the overall survival follow-up of a study is allowed.)
6. Any prior treatment of antibody/drug that targets at T-cell coregulatory proteins (immune checkpoints, including PD-1, PD-L1, CTLA4, TIM3 and LAG3, etc.).
7. Subjects with current active autoimmune disease or prior history of autoimmune disease that probably will relapse or at risk of having these conditions.
8. Immune deficient disease or systemic corticosteroid treatment within 7 days prior to the first dose of investigational product, or any other form of immune suppressing treatment.
9. A known additional malignancy within 5 years prior to the first dose of investigational product.
10. History of inflammatory bowel disease or active inflammatory bowel disease (for example Crohn's disease or ulcerative colitis).
11. Known history of human immunodeficiency virus (HIV) infection and/or acquired immune deficiency syndrome.
12. Subjects at active phase of chronic hepatitis B or with active hepatitis C.
13. History of organ transplantation.
14. Subjects with known history of alcoholism or drugs abuse.
15. Severe allergic reaction to other monoclonal antibodies.
16. QTc interval > 480 msec on the screening electrocardiogram (ECG) (as calculated by Fridericia formula).
17. Subjects with other conditions that in the investigator's opinion may influence subject's compliance or make subjects not suitable for participating in this trial.

Contacts and Locations

Locations

China, Guangdong

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510080

Sponsors and Collaborators

CStone Pharmaceuticals

Investigators

• Principal Investigator: Qing Zhou; Guangdong Provincial People's Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14.

• Responsible Party: CStone Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT03728556
• Other Study ID Numbers: CS1001-301; CTR20181429 ( Other Identifier: www.chinadrugtrials.org.cn )
• First Posted: November 2, 2018
• Last Update Posted: June 15, 2023
• Last Verified: June 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Antibodies; Antibodies, Monoclonal; Immunologic Factors; Physiological Effects of Drugs